---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-191487"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:00:35.846586+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Reports Q1 2026 Net Loss of $158.3M, Cash of $603M; Phase 3 Obesity Trials Fully Enrolled

## Summary
- Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.
- Initiation of Phase 3 trial for oral VK2735 expected in 4Q26; Phase 2 VENTURE-Oral showed up to 12.2% weight loss after 13 weeks.
- Maintenance dosing study for VK2735 is ongoing with data expected in 3Q26; the study explores weekly, every-other-week, and monthly dosing.
- IND filed for novel amylin agonist VK3019; Phase 1 trial initiation planned for 2Q26.
- First quarter 2026 cash position was $603 million, with R&D expenses of $150.2 million and net loss of $158.3 million, compared to $45.6 million net loss in Q1 2025.

## SEC filing metadata
- accession: 0001193125-26-191487
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/0001193125-26-191487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-20260429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-191487
- JSON: https://secwatch.observer/filing/0001193125-26-191487.json
- Plain text: https://secwatch.observer/filing/0001193125-26-191487.txt

## Key facts
- Earnings Releases
  Viking Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On April 29, 2026, we issued a press release reporting our financial results for the first quarter ended March 31, 2026 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/0001193125-26-191487-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.